Long-term survival of transplanted organ requires use of anti-rejection medications
Plexision, a Pittsburgh-based biotechnology company, has initiated overseas operations with the establishment of a reference laboratory in Hyderabad for offering a comprehensive range of tests for transplant patients.
These tests include the company’s exclusive personalized transplant diagnostic tests to predict rejection and viral infections, as well as drug level monitoring, pharmacogenomics and genetic testing, the company said on 14 Oct 2022.
Recently, the company’s products were showcased at the annual meeting of the Indian Society for Organ Transplantation in Nagpur. The products will become available later this year.
Long-term survival of a transplanted organ requires lifelong use of anti-rejection medications to prevent rejection, while avoiding overdosing which can increase the risk of infections and cancers.
“The success of anti-rejection medications depends on the unique metabolic, immunological and genetic makeup of each individual,” said Ravi Mohanka, MD, President of the Indian Society of Transplantation, and Director of Liver Transplantation at the Sir H.N Reliance Foundation Hospital and Research Center in Mumbai.
“Plexision’s test systems can define this complex makeup to personalize care and improve outcomes in the rapidly growing transplant recipient population in India,” added Rajeev Sindhi, CEO of Plexision.
The Global Depository of Donation and Transplantation notes that 12,343 liver and kidney transplants were performed in India in 2019. These numbers included 10,604 living donor transplants, the highest compared with any other country. These numbers are expected to increase substantially in 2022, following a temporary decline during the COVID-19 pandemic.
Plexision performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. The company’s reference laboratory in Pittsburgh is CLIA-approved, CAP-accredited and GMP-compliant. fiinews.com
